Hunan Fangsheng Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Hunan Fangsheng Pharmaceutical has a total shareholder equity of CN¥1.6B and total debt of CN¥739.7M, which brings its debt-to-equity ratio to 45.5%. Its total assets and total liabilities are CN¥3.2B and CN¥1.6B respectively. Hunan Fangsheng Pharmaceutical's EBIT is CN¥207.4M making its interest coverage ratio 23.3. It has cash and short-term investments of CN¥217.5M.
Key information
45.5%
Debt to equity ratio
CN¥739.68m
Debt
| Interest coverage ratio | 23.3x |
| Cash | CN¥217.51m |
| Equity | CN¥1.63b |
| Total liabilities | CN¥1.60b |
| Total assets | CN¥3.23b |
Recent financial health updates
No updates
Recent updates
The Market Doesn't Like What It Sees From Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) Earnings Yet
Jun 06
Earnings Troubles May Signal Larger Issues for Hunan Fangsheng Pharmaceutical (SHSE:603998) Shareholders
Apr 30Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) 34% Share Price Surge Not Quite Adding Up
Mar 04Financial Position Analysis
Short Term Liabilities: 603998's short term assets (CN¥1.0B) do not cover its short term liabilities (CN¥1.4B).
Long Term Liabilities: 603998's short term assets (CN¥1.0B) exceed its long term liabilities (CN¥212.9M).
Debt to Equity History and Analysis
Debt Level: 603998's net debt to equity ratio (32.1%) is considered satisfactory.
Reducing Debt: 603998's debt to equity ratio has increased from 17.7% to 45.5% over the past 5 years.
Debt Coverage: 603998's debt is well covered by operating cash flow (28.2%).
Interest Coverage: 603998's interest payments on its debt are well covered by EBIT (23.3x coverage).